Dirençli Epilepsinin Medikal Tedavisi

Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE commission on therapeutic strategies: definition of drug resistant epilepsy. Epilepsia. 2009;51(6):1069–1077. doi:10.1111/j.1528-1167.2009.02397.x

Brodie MJ, Barry SJE, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78(20):1548–1554. doi:10.1212/ WNL.0b013e3182563b19

Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314–319. doi:10.1056/ NEJM200002033420503

Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology. 2008;70 (1):54–65. doi:10.1212/01.wnl.0000286959.22040.6e

Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279. doi:10.1001/ jamaneurol.2017.3949

Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol. 2007;62(4):382–389. doi:10.1002/ana.21166

Luciano AL, Shorvon SD. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol. 2007;62(4):375–381. doi:10.1002/ana.21064

Callaghan B, Schlesinger M, Rodemer W, et al. Remission and relapse in a drug-resistant epilepsy population followed prospectively: drug-resistant epilepsy population. Epilepsia. 2011;52 (3):619–626. doi:10.1111/j.1528-1167.2010.02929.x

Ryvlin P, Cucherat M, Rheims S. Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treat

ment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. Lancet Neurol. 2011;10 (11):961–968. doi:10.1016/S1474-4422(11)70193-4

Choi H, Hayat MJ, Zhang R, et al. Drug-resistant epilepsy in adults: outcome trajectories after failure of two medications. Epilepsia. 2016;57(7):1152–1160. doi:10.1111/epi.13406

Zaccara G, Mula M, Ferrò B, et al. Do neurologists agree in diagnosing drug resistance in adults with focal epilepsy? Epilepsia. 2019;60(1):175–183. doi:10.1111/epi.14622

O’ Rourke G, O’ Brien JJ. Identifying the barriers to antiepileptic drug adherence among adults with epilepsy. Seizure. 2017;45:160–168. doi:10.1016/j.seizure.2016.12.006

Anzellotti F, Dono F, Evangelista G, et al. Psychogenic non-epileptic seizures and pseudo-refractory epilepsy, a management challenge. Front Neurol. 2020;11:461. doi:10.3389/fneur.2020.00461

14.Thomas P, Valton L, Genton P. Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain. 2006;129(5):1281–1292. doi:10.1093/brain/awl047

Boylan LS, Labovitz DL, Jackson SC, Starner K, Devinsky O. Auras are frequent in idiopathic generalized epilepsy. Neurology. 2006;67(2):343–345. doi:10.1212/01.wnl.0000225185.37081.97

Lombroso CT. Consistent EEG focalities detected in subjects with primary generalized epilepsies monitored for two decades. Epilepsia. 1997;38(7):797–812. doi:10.1111/j.1528-1157.1997.tb01467.x

Kellinghaus C, Lüders HO. Frontal lobe epilepsy. Epileptic Disord. 2004;6(4):223–239.

Kalilani L, Sun X, Pelgrims B, Noack-Rink M, Villanueva V. The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis. Epilepsia. 2018;59(12):2179–2193. doi:10.1111/ epi.14596

Marson A, Jacoby A, Johnson A, et al. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet. 2005;365(9476):2007–2013. doi:10.1016/S0140-6736(05)66694-9

An S, Malhotra K, Dilley C, et al. Predicting drug-resistant epilepsy — a machine learning approach based on administrative claims data. Epilepsy Behavior. 2018;89:118–125. doi:10.1016/j. yebeh.2018.10.013

Mohanraj R, Brodie MJ. Outcomes of newly diagnosed idiopathic generalized epilepsy syndromes in a non-pediatric setting. Acta Neurol Scand. 2007;115(3):204–208. doi:10.1111/j.1600-0404.2006.00791.x

Szaflarski JP, Lindsell CJ, Zakaria T, Banks C, Privitera MD. Seizure control in patients with idiopathic generalized epilepsies: EEG determinants of medication response. Epilepsy Behavior. 2010;17(4):525–530. doi:10.1016/j.yebeh.2010.02.005

Holtkamp M, Kowski AB, Merkle H, Janz D. Long-term outcome in epilepsy with grand mal on awakening: forty years of follow-up. Ann Neurol. 2014;75(2):298–302. doi:10.1002/ana.24103

Senf P, Schmitz B, Holtkamp M, Janz D. Prognosis of juvenile myoclonic epilepsy 45 years after onset: seizure outcome and predictors. Neurology. 2013;81(24):2128–2133. doi:10.1212/01. wnl.0000437303.36064.f8

Catarino CB, Liu JYW, Liagkouras I, et al. Dravet syndrome as epileptic encephalopathy: evidence from long-term course and neuropathology. Brain. 2011;134(10):2982–3010. doi:10.1093/ brain/awr129

Genton P, Velizarova R, Dravet C. Dravet syndrome: the long-term outcome: long-term outcome. Epilepsia. 2011;52:44–49. doi:10.1111/j.1528-1167.2011.03001.x

Singh R, Scheffer IE, Crossland K, Berkovic SF. Generalized epilepsy with febrile seizures plus: a common childhood-onset genetic epilepsy syndrome. Ann Neurol. 1999;45(1):75–81. doi:10.1002/1531-8249(199901)45:1<75::aid-art13>3.0.co;2-w

Margari L, Legrottaglie AR, Vincenti A, et al. Association between SCN1A gene polymorphisms and drug resistant epilepsy in pediatric patients. Seizure. 2018;55:30–35. doi:10.1016/j. seizure.2018.01.002

Roy PL, Ronquillo LH, Ladino LD, Tellez-Zenteno JF. Risk factors associated with drug resistant focal epilepsy in adults: a case control study. Seizure. 2019;73:46–50. doi:10.1016/j. seizure.2019.10.020

Semah F, Picot M-C, Adam C, et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology. 1998;51(5):1256–1262. doi:10.1212/WNL.51.5.1256

Perucca E, French J, Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol. 2007;6(9):793–804. doi:10.1016/S1474-4422(07)70215-6

Beghi E, Gatti G, Tonini C, et al. Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res. 2003;57(1):1–13. doi:10.1016/j.eplepsyres.2003.09.007

Millul A, Iudice A, Adami M, et al. Alternative monotherapy or add-on therapy in patients with epilepsy whose seizures do not respond to the first monotherapy: an Italian multicenter prospec-tive observational study. Epilepsy Behav. 2013;28(3):494–500. doi:10.1016/j.yebeh.2013.05.038

Brodie MJ, Yuen AWC. Lamotrigine substitution study: evidence for synergism with sodium valproate? Epilepsy Res. 1997;26 (3):423–432. doi:10.1016/S0920-1211(96)01007-8

Chiron C, Marchand M, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. Lancet. 2000;356(9242):1638–1642. doi:10.1016/S0140-6736(00)03157-3

Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011–2020. doi:10.1056/NEJMoa1611618

Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11(9):792–802. doi:10.1016/S1474-4422(12)70153-9

Gilliam FG, Fessler AJ, Baker G, Vahle V, Carter J, Attarian H. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology. 2004;62(1):23–27. doi:10.1212/WNL.62.1.23

Perucca P, Carter J, Vahle V, Gilliam FG. Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy. Neurology. 2009;72(14):1223–1229. doi:10.1212/01. wnl.0000345667.45642.61

Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia. 1998;39(1):5–17. doi:10.1111/j.1528-1157.1998.tb01268.x

Rheims S, Ryvlin P. Pharmacotherapy for tonic–clonic seizures. Expert Opin Pharmacother. 2014;15(10):1417–1426. doi:10.1517/14656566.2014.915029

Rheims S, Perucca E, Cucherat M, Ryvlin P. Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis: response to AEDs in Randomized Trials. Epilepsia. 2011. doi:10.1111/j.1528- 1167.2010.02915.x

Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19 (1):38–48. doi:10.1016/S1474-4422(19)30399-0

Hemery C, Ryvlin P, Rheims S. Prevention of generalized tonic-clonic seizures in refractory focal epilepsy: a meta-analysis. Epilepsia. 2014;55(11):1789–1799. doi:10.1111/ epi.12765

Arzimanoglou A, French J, Blume WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, man-agement, and trial methodology. Lancet Neurol. 2009;8(1):82–93. doi:10.1016/S1474-4422(08)70292-8

Guery D, Rheims S. Is the mechanism of action of antiseizure drugs a key element in the choice of treatment? Fundam Clin Pharmacol. 2020;fcp.12614. doi:10.1111/fcp.12614

Trinka E, Brigo F. Antiepileptogenesis in humans: disappoint-ing clinical evidence and ways to move forward. Curr Opin Neurol. 2014;27(2):227–235. doi:10.1097/ WCO.0000000000000067

French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a Phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388 (10056):2153–2163. doi:10.1016/S0140-6736(16)31419-2

Mirzaa GM, Campbell CD, Solovieff N, et al. Association of MTOR mutations with developmental brain disorders, including megalencephaly, focal cortical dysplasia, and pigmentary mosaicism. JAMA Neurol. 2016;73(7):836. doi:10.1001/ jamaneurol.2016.0363

Baldassari S, Ribierre T, Marsan E, et al. Dissecting the genetic basis of focal cortical dysplasia: a large cohort study. Acta Neuropathol. 2019;138(6):885–900. doi:10.1007/s00401-019-02061-5

Griffith JL, Wong M. The mTOR pathway in treatment of epi-lepsy: a clinical update. Future Neurol. 2018;13(2):49–58. doi:10.2217/fnl-2018-0001

Klepper J, Akman C, Armeno M, et al. Glut1 Deficiency Syndrome (Glut1DS): state of the art in 2020 and recommenda-tions of the international Glut1DS study group. Epilepsia Open. 2020;5(3):354–365. doi:10.1002/epi4.12414

Lagae L, Sullivan J, Knupp K, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019;394 (10216):2243–2254. doi:10.1016/S0140-6736(19)32500-0

Hatini PG, Commons KG. Serotonin abnormalities in Dravet syndrome mice before and after the age of seizure onset. Brain Res. 2019;1724:146399. doi:10.1016/j.brainres.2019.146399

Griffin AL, Jaishankar P, Grandjean J-M, Olson SH, Renslo AR, Baraban SC. Zebrafish studies identify serotonin receptors med-iating antiepileptic activity in Dravet syndrome. Brain Commun. 2019;1(1):fcz008. doi:10.1093/braincomms/fcz008

Griffin A, Hamling KR, Knupp K, Hong S, Lee LP, Baraban SC. Clemizole and modulators of serotonin signalling suppress sei-zures in Dravet syndrome. Brain. 2017;aww342. doi:10.1093/ brain/aww342

Ihara Y, Tomonoh Y, Deshimaru M, et al. Retigabine, a Kv7.2/ Kv7.3-channel opener, attenuates drug-induced seizures in knock-in mice harboring Kcnq2 Mutations. PLoS One. 2016;11 (2):e0150095. doi:10.1371/journal.pone.0150095

Rheims S, Auvin S. Attention deficit/hyperactivity disorder and epilepsy. Curr Opin Neurol. 2021;34(2):219–225. doi:10.1097/ WCO.0000000000000903

Sherman EMS, Slick DJ, Connolly MB, Eyrl KL. ADHD, Neurological correlates and health-related quality of life in severe pediatric epilepsy. Epilepsia. 2007;48(6):1083–1091. doi:10.1111/ j.1528-1167.2007.01028.x

Perucca E. Clinical pharmacokinetics of new-generation antiepi-leptic drugs at the extremes of age. Clin Pharmacokinet. 2006;45 (4):351–363. doi:10.2165/00003088-200645040-00002

Sirven JI, Fife TD, Wingerchuk DM, Drazkowski JF. Second- generation antiepileptic drugs’ impact on balance: a meta- analysis. Mayo Clin Proc. 2007;82(1):40–47. doi:10.4065/82.1.40

Finkle WD, Der JS, Greenland S, et al. Risk of fractures requiring hospitalization after an initial prescription for zolpidem, alprazo-lam, lorazepam, or diazepam in older adults. J Am Geriatr Soc. 2011;59(10):1883–1890. doi:10.1111/j.1532-5415.2011.03591.x

Tomson T, Battino D, Bromley R, et al. Management of epilepsy in pregnancy: a report from the International league against epi-lepsy task force on women and pregnancy. Epileptic Disord. 2019;21(6):497–517. doi:10.1684/epd.2019.1105

Keni RR, Jose M, Sarma PS, Thomas SV. For the Kerala Registry of Epilepsy and Pregnancy Study Group. Teratogenicity of antiepileptic dual therapy: dose-dependent, drug-specific, or both? Neurology. 2018;90(9):e790–e796. doi:10.1212/WNL.0000000000005031

Verrotti A, Tambucci R, Di Francesco L, et al. The role of polytherapy in the management of epilepsy: suggestions for rational antiepileptic drug selection. Expert Rev Neurother. 2020;20(2):167–173. doi:10.1080/14737175.2020.1707668

Stephen LJ, Forsyth M, Kelly K, Brodie MJ. Antiepileptic drug combinations—Have newer agents altered clinical outcomes? Epilepsy Res. 2012;98(2–3):194–198. doi:10.1016/j. eplepsyres.2011.09.008

Jonker DM, Voskuyl RA, Danhof M. Synergistic Combinations of Anticonvulsant Agents: what Is the Evidence from Animal Experiments? Epilepsia. 2007;48(3):412–434. doi:10.1111/ j.1528-1167.2006.00952.x

Stafstrom CE. Mechanisms of action of antiepileptic drugs: the search for synergy. Curr Opin Neurol. 2010;23(2):157–163. doi:10.1097/WCO.0b013e32833735b5

Sake J-K, Hebert D, Isojärvi J, et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs. 2010;24 (12):1055–1068. doi:10.2165/11587550-000000000-00000

Besag FMC, Berry DJ, Pool F, Newbery -J-JE, Subel B. Carbamazepine Toxicity with Lamotrigine: pharmacokinetic or Pharmacodynamic Interaction? Epilepsia. 1998;39(2):183–187. doi:10.1111/j.1528-1157.1998.tb01356.x